Utah Medical Products Inc.
Utah Medical Products Inc. (UTMD): 2 pipeline candidates · 2 upcoming catalysts · ~101 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
100.8 months
D/E 0.03 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
2 upcoming, next in ~1748d
N/A
A transparent, data-derived signal for Utah Medical Products Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$216.0M
Cash
$87.4M
Quarterly Burn
$2.7M
Runway
100.8 mo
Revenue
$8.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| nectero east system | Phase 2/Phase 3 |
| optimal medical therapy | — |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$140.9M
| Holder | Shares | Value |
|---|---|---|
| brandes investment partners, lp | 449,279 | $27.9M |
| vanguard capital management llc | 277,120 | $17.2M |
| dimensional fund advisors lp | 197,908 | $12.3M |
| blackrock, inc. | 187,649 | $11.6M |
| renaissance technologies llc | 184,114 | $11.4M |
| geode capital management, llc | 120,097 | $7.4M |
| hotchkis & wiley capital management llc | 89,131 | $5.5M |
| rice hall james & associates, llc | 67,882 | $4.2M |
| state street corp | 64,402 | $4.0M |
| morgan stanley | 48,801 | $3.0M |
Showing top 10 of 119 institutional holders of Utah Medical Products Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Utah Medical Products Inc.'s pipeline?
Utah Medical Products Inc. (UTMD) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Utah Medical Products Inc.'s lead drug candidate?
Utah Medical Products Inc.'s most advanced tracked candidate is nectero east system (Phase 2/Phase 3) for Abdominal Aortic Aneurysm.
What is Utah Medical Products Inc.'s next catalyst?
Utah Medical Products Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus" — expected April 1, 2031.
What is Utah Medical Products Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Utah Medical Products Inc. has approximately 100.8 months of cash runway.
What is Utah Medical Products Inc.'s market capitalization?
Utah Medical Products Inc.'s market capitalization is approximately $216.0M.
Get the full picture on Utah Medical Products Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.